#DYK ~50M Americans are living with an autoimmune disease? At Synthekine, we’re advancing next-gen selective cytokine therapeutics with the potential to change the treatment paradigm for autoimmune diseases. Learn more: #AutoimmuneAwarenessMonth

We look forward to presenting at @KeystoneSymp conferences next week! Join us in Banff to learn more about our approaches to IL-2 in cancer immunotherapy and cell therapy:. #KSCancerImmune25 #KSCellTherapy25

We look forward to presenting at @BiocomCA's Global Life Science Partnering & Investor Conference. Join us as we discuss our latest advancements for #cancer, #autoimmune, and #inflammatory diseases. #BiocomGPIC

Yesterday at #ASH24, we presented positive initial results from our Phase 1 study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ hematologic malignancies. Learn more about our results: . @ASH_hematology

#DYK Lung cancer is the most common cause of #cancer death in the United States? This Lung Cancer Awareness Month, join us in raising awareness, supporting ongoing research, and honoring the strength and resilience of those impacted by #LungCancer. #LCAM2024

#ICYMI our CEO, Debanjan Ray, joined other past #Fierce15 honorees on stage at the @FierceBiotech Summit to share recent company progress & discuss the groundbreaking work shaping the future of #biotech. To explore collaboration opportunities, contact us at bd@synthekine.com

Our scientific founder, Dr. Christopher Garcia shared insights into how protein engineering is transforming the landscape of treatment for #cancer and #autoimmune diseases in a recent episode of the @timmermanreport’s The Long Run podcast. Listen here:

Tomorrow, we will present preclinical data on STK-009 + SYNCAR-001, our orthogonal IL-2 & CD19 #CART investigational therapy, at the @ACRheum Convergence. These results demonstrate its potential to treat autoimmune diseases w/o requiring lymphodepletion.

Today, we presented positive translational data of our first-in-class α/β-IL-2R biased partial agonist, STK-012, and preclinical and GLP toxicology data on our biased IL-12 cytokine partial agonist, STK-026, at #SITC24. Learn more:

We look forward to presenting data from multiple abstracts at the 12th Annual Meeting of the @CytokineSociety (ICIS) jointly held with the Korean Association of Immunologists International Meeting this month! See our poster and presentation details below:.#Cytokines2024 #KAI2024

Our CMO, Naiyer Rizvi, M.D., has co-authored a journal article published in @NatureMedicine! His insights have not only deepened our knowledge but also advanced the understanding of others in the field of #immunotherapy for #cancer treatment.

Join us at the #FierceBiotechSummit today, where our CEO, Debanjan Ray, will join other past #Fierce15 honorees to discuss recent company milestones and share insights, experiences and visions for the evolving #biotech landscape. @LifeSciEvents

Our CSO, Martin Oft, M.D., will be sharing key insights from our Phase 1 study of STK-012, our first-in-class α/β-biased IL-2 partial agonist for patients with advanced solid tumors, at “The Promise of Interleukin-2 Therapy Conference” in Paris, France:

Today, we announced that the #FDA has granted Fast Track designation to SYNCAR-001 + STK-009, our CD19 #CART and orthogonal IL-2 investigational therapy, for the treatment of systemic #lupus erythematosus (#SLE), without the use of lymphodepletion:

#DYK Lung cancer is the leading cause of cancer death in the United States, accounting for an estimated 1 in 5 of all cancer deaths? On #WorldLungCancerDay, join us as we raise awareness and support the countless individuals and families impacted by lung cancer. #WLCD2024

Alex Azrilevich, Pharm.D., our VP, Clinical Development, will be presenting on the promising potential of STK-012, our first-in-class α/β-biased IL-2 partial agonist for patients with advanced solid tumors, at #KCRS24. Learn more:

Our Scientific Founder, Christopher Garcia, Ph.D., was recently awarded the 2024 Passano Award for his research on the structural and mechanistic biology of cell surface receptors and its implications for safer, more effective treatments. More here:

Next week, our VP of Business Development, Kunal Patel, will be speaking on a panel discussing best practices for partnerships in the #biotech industry at the BIO International Convention in San Diego, CA. Learn more: #BIO2024

#BIO2024 is almost here! We look forward to gathering with the broader life sciences community where business and breakthroughs converge at the world’s largest #biotech gathering June 3-6 in San Diego, CA. Send us a meeting request to connect on-site:

Today, on #EarthDay, we reiterate our commitment to making a positive impact on the environment, from reducing our ecological footprint to promoting eco-friendly practices throughout our operations. Discover how we've taken meaningful action to protect and preserve our planet: